Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib

In 2020, a 45-year-old woman was started on fulvestrant and abemaciclib therapy to treat breast cancer which had recurred in her left breast after surgery. We were able to control her cancer using this treatment; however, the ground-glass opacity in the lower lobe of her right lung expanded, along w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitarai, Yuki, Tsubata, Yukari, Hyakudomi, Miki, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888010/
https://www.ncbi.nlm.nih.gov/pubmed/35251813
http://dx.doi.org/10.7759/cureus.21741
_version_ 1784661028111384576
author Mitarai, Yuki
Tsubata, Yukari
Hyakudomi, Miki
Isobe, Takeshi
author_facet Mitarai, Yuki
Tsubata, Yukari
Hyakudomi, Miki
Isobe, Takeshi
author_sort Mitarai, Yuki
collection PubMed
description In 2020, a 45-year-old woman was started on fulvestrant and abemaciclib therapy to treat breast cancer which had recurred in her left breast after surgery. We were able to control her cancer using this treatment; however, the ground-glass opacity in the lower lobe of her right lung expanded, along with an increase in her peripheral blood eosinophil count. She was referred to the respiratory medicine department for a detailed examination including bronchoscopy. We discovered a high proportion of eosinophils in her bronchoalveolar lavage fluid and diagnosed the condition as drug-induced eosinophilic pneumonia. The ground-glass change improved after steroid administration. In this case, the adverse effects of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor playing an essential role in breast cancer treatment, were discovered by combining blood, imaging, and bronchoalveolar lavage fluid findings. This contributed to an early introduction of treatment and prevented the deterioration of her quality of life.
format Online
Article
Text
id pubmed-8888010
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88880102022-03-03 Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib Mitarai, Yuki Tsubata, Yukari Hyakudomi, Miki Isobe, Takeshi Cureus Internal Medicine In 2020, a 45-year-old woman was started on fulvestrant and abemaciclib therapy to treat breast cancer which had recurred in her left breast after surgery. We were able to control her cancer using this treatment; however, the ground-glass opacity in the lower lobe of her right lung expanded, along with an increase in her peripheral blood eosinophil count. She was referred to the respiratory medicine department for a detailed examination including bronchoscopy. We discovered a high proportion of eosinophils in her bronchoalveolar lavage fluid and diagnosed the condition as drug-induced eosinophilic pneumonia. The ground-glass change improved after steroid administration. In this case, the adverse effects of abemaciclib, a cyclin-dependent kinase 4/6 inhibitor playing an essential role in breast cancer treatment, were discovered by combining blood, imaging, and bronchoalveolar lavage fluid findings. This contributed to an early introduction of treatment and prevented the deterioration of her quality of life. Cureus 2022-01-30 /pmc/articles/PMC8888010/ /pubmed/35251813 http://dx.doi.org/10.7759/cureus.21741 Text en Copyright © 2022, Mitarai et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Mitarai, Yuki
Tsubata, Yukari
Hyakudomi, Miki
Isobe, Takeshi
Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
title Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
title_full Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
title_fullStr Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
title_full_unstemmed Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
title_short Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
title_sort drug-induced eosinophilic pneumonia as an adverse event of abemaciclib
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888010/
https://www.ncbi.nlm.nih.gov/pubmed/35251813
http://dx.doi.org/10.7759/cureus.21741
work_keys_str_mv AT mitaraiyuki druginducedeosinophilicpneumoniaasanadverseeventofabemaciclib
AT tsubatayukari druginducedeosinophilicpneumoniaasanadverseeventofabemaciclib
AT hyakudomimiki druginducedeosinophilicpneumoniaasanadverseeventofabemaciclib
AT isobetakeshi druginducedeosinophilicpneumoniaasanadverseeventofabemaciclib